Early TAVR Beneficial for Asymptomatic Severe Aortic Stenosis
By Elana Gotkine HealthDay Reporter
FRIDAY, Nov. 1, 2024 -- Early transcatheter aortic valve replacement (TAVR) is better than clinical surveillance for reducing the incidence of death, stroke, and unplanned hospitalization for cardiovascular causes among patients with asymptomatic severe aortic stenosis, according to a study published online Oct. 28 in the New England Journal of Medicine. The research was published to coincide with the annual Transcatheter Cardiovascular Therapeutics conference, held from Oct. 27 to 30 in Washington, D.C.
Philippe Généreux, M.D., from Morristown Medical Center in New Jersey, and colleagues randomly assigned patients from 75 centers with asymptomatic severe aortic stenosis to undergo early TAVR with transfemoral placement of a balloon-expandable valve or clinical surveillance (455 and 446 patients, respectively).
The researchers found that 26.8 and 45.3 percent of patients in the TAVR and clinical surveillance groups had a primary end point event (composite of death, stroke, or unplanned hospitalization for cardiovascular causes; hazard ratio, 0.50). Among patients assigned to TAVR and clinical surveillance, death occurred in 8.4 and 9.2 percent, respectively; stroke in 4.2 and 6.7 percent; and unplanned hospitalization for cardiovascular causes in 20.9 and 41.7 percent. Eighty-seven percent of patients in the clinical surveillance group underwent aortic valve replacement during a median follow-up of 3.8 years.
"Among patients with asymptomatic severe aortic stenosis, a strategy of early TAVR was superior to guideline-recommended clinical surveillance in reducing the composite end point of death, stroke, or unplanned hospitalization for cardiovascular causes," the authors write.
The study was funded by Edwards Lifesciences.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-02 06:00
Read more
- CDC Lowers Age for First Pneumococcal Vaccine to 50
- Autism Diagnoses Rising Among U.S. Children, Adults
- Doctors Report First U.S. Cases of Sexually Transmitted Ringworm Rash
- Avadel Pharmaceuticals Announces FDA Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
- ED Visit Rate 36.1 per 1,000 Older Adults With Alzheimer Disease
- FDA Approves Orlynvah (sulopenem etzadroxil and probenecid) for the Treatment of Uncomplicated Urinary Tract Infections
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions